

DAFTAR PUSTAKA

- Anderson, T., Lane, A.R. and Hackney, A.C. (2016) “Cortisol and testosterone dynamics following exhaustive endurance exercise,” *European Journal of Applied Physiology*, 116(8), pp. 1503–1509. Available at: <https://doi.org/10.1007/s00421-016-3406-y>.
- Argenti, D., Jensen, B.K., Hensel, R., Bordeaux, K., Schleimer, R., Bickel, C. and Heald, D. (2000) “A Mass Balance Study to Evaluate the Biotransformation and Excretion of [¹⁴ C]-Triamcinolone Acetonide following Oral Administration,” *The Journal of Clinical Pharmacology*, 40(7), pp. 770–780. Available at: <https://doi.org/10.1177/00912700022009413>.
- Argenti, D., Shah, B. and Heald, D. (1999) “A Pharmacokinetic Study to Evaluate the Absolute Bioavailability of Triamcinolone Acetonide following Inhalation Administration,” *The Journal of Clinical Pharmacology*, 39(7), pp. 695–702. Available at: <https://doi.org/10.1177/00912709922008335>.
- Arlettaz, A., Collomp, K., Portier, H., Lecoq, A.-M., Pelle, A. and de Ceaurreiz, J. (2006) “Effects of Acute Prednisolone Intake During Intense Submaximal Exercise,” *International Journal of Sports Medicine*, 27(9), pp. 673–679. Available at: <https://doi.org/10.1055/s-2005-872826>.
- Arlettaz, A., Collomp, K., Portier, H., Lecoq, A.-M., Rieth, N., Panse, B. le and Ceaurreiz, J. de (2008) “Effects of acute prednisolone administration on exercise endurance and metabolism,” *British Journal of Sports Medicine*, 42(4), pp. 250–254. Available at: <https://doi.org/10.1136/bjism.2007.039040>.
- Arlettaz, A., Portier, H., Lecoq, A.-M., Rieth, N., de Ceaurreiz, J. and Collomp, K. (2007) “Effects of short-term prednisolone intake during submaximal exercise,” *Medicine and Science in Sports and Exercise*, 39(9), pp. 1672–1678. Available at: <https://doi.org/10.1249/mss.0b013e3180dc992c>.
- Bethesda (2012) *Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]*.
- Bjornsdottir, H.H., Einarsson, Ó.B., Gröndal, G. and Gudbjornsson, B. (2024) “Nationwide prevalence of glucocorticoid prescriptions over 17 years and osteoporosis prevention among long-term users,” *SAGE Open Medicine*, 12. Available at: <https://doi.org/10.1177/20503121241235056>.
- Braun, T.P. and Marks, D.L. (2015) “The regulation of muscle mass by endogenous glucocorticoids,” *Frontiers in Physiology*, 6. Available at: <https://doi.org/10.3389/fphys.2015.00012>.

- Brien, T.G. (1981) "Human corticosteroid binding globulin," *Clin Endocrinol (Oxf)*, 14(2).
- Brunton, L.L., Hilal-Dandan, R. and Knollmann, B.C. (2018) *Goodman & Gilman's the pharmacological basis of therapeutics*. 13th ed. McGraw-Hill Education.
- Castle-Kirszbaum, M., Goldschlager, T., Shi, M.D.Y. and Fuller, P.J. (2023) "Glucocorticoids and Water Balance: Implications for Hyponatremia Management and Pituitary Surgery," *Neuroendocrinology*, 113(8), pp. 785–794. Available at: <https://doi.org/10.1159/000530701>.
- Chourpiliadis, C. and Aeddula, N.R. (2023) *Physiology, Glucocorticoids, StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing*.
- Collomp, K., Arlettaz, A., Buisson, C., Lecoq, A.M. and Mongongu, C. (2016) "Glucocorticoid administration in athletes: performance, metabolism and detection," *Steroids*, 115.
- Cooper, M.S. and Stewart, P.M. (2009) "11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation," *J Clin Endocrinol Metab*, 94(12).
- Coutinho, A.E. and Chapman, K.E. (2011) "The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights," *Molecular and Cellular Endocrinology*, 335(1), pp. 2–13. Available at: <https://doi.org/10.1016/j.mce.2010.04.005>.
- Cruz-Topete, D., Oakley, R.H. and Cidlowski, J.A. (2020) "Glucocorticoid Signaling and the Aging Heart," *Frontiers in Endocrinology*, 11. Available at: <https://doi.org/10.3389/fendo.2020.00347>.
- Curtis, J.R., Westfall, A.O., Allison, J., Bijlsma, J.W., Freeman, A., George, V., Kovac, S.H., Spettell, C.M. and Saag, K.G. (2006) "Population-based assessment of adverse events associated with long-term glucocorticoid use," *Arthritis & Rheumatism*, 55(3), pp. 420–426. Available at: <https://doi.org/10.1002/art.21984>.
- Davoren, A.K., Rulison, K., Milroy, J., Grist, P., Fedoruk, M., Lewis, L. and Wyrick, D. (2024a) "Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code," *Sports Medicine - Open*, 10(1). Available at: <https://doi.org/10.1186/s40798-024-00721-9>.
- Davoren, A.K., Rulison, K., Milroy, J., Grist, P., Fedoruk, M., Lewis, L. and Wyrick, D. (2024b) "Doping Prevalence among U.S. Elite Athletes Subject to Drug Testing under the World Anti-Doping Code," *Sports Med Open*, 10(1).
- Deng, J., Chalhoub, N.E., Sherwin, C.M., Li, C. and Brunner, H.I. (2019) "Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus," *Seminars in Arthritis and*

Rheumatism, 49(2), pp. 251–259. Available at:
<https://doi.org/10.1016/j.semarthrit.2019.03.010>.

Derendorf, H., Möllmann, H., Barth, J., Möllmann, C., Tunn, S. and Krieg, M. (1991a) “Pharmacokinetics and Oral Bioavailability of Hydrocortisone,” *The Journal of Clinical Pharmacology*, 31(5), pp. 473–476. Available at:
<https://doi.org/10.1002/j.1552-4604.1991.tb01906.x>.

Derendorf, H., Möllmann, H., Barth, J., Möllmann, C., Tunn, S. and Krieg, M. (1991b) “Pharmacokinetics and Oral Bioavailability of Hydrocortisone,” *The Journal of Clinical Pharmacology*, 31(5), pp. 473–476. Available at:
<https://doi.org/10.1002/j.1552-4604.1991.tb01906.x>.

Diederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W. and Bähr, V. (2002) “11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids,” *J Clin Endocrinol Metab*, 87(12).

Diederich, S., Hanke, B., Burkhardt, P., Müller, M., Schöneshöfer, M., Bähr, V. and Oelkers, W. (1998) “Metabolism of synthetic corticosteroids by 11 beta-hydroxysteroid-dehydrogenases in man,” *Steroids*, 63(5–6).

Dinas Kesehatan Kota Yogyakarta (2020) *Penandaan Kemasan Obat Berdasarkan Golongan Obat*, kesehatan.jogjakota.go.id.

Draper, N. and Stewart, P.M. (2005) “11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action,” *J Endocrinol*, 186(2).

Duclos, M. (2010) “Evidence on Ergogenic Action of Glucocorticoids as a Doping Agent Risk,” *The Physician and Sportsmedicine*, 38(3), pp. 121–127. Available at: <https://doi.org/10.3810/psm.2010.10.1817>.

Duclos, M., Guinot, M., le Buoc, Y. and Cortisol, G.H. (2007) “Odd and controversial ideas,” *Appl Physiol Nutr Metab*, 32(5).

Dvorak, J., Feddermann, N. and Grimm, K. (2006) “Glucocorticosteroids in football: use and misuse,” *British Journal of Sports Medicine*, 40(Supplement 1), pp. i48–i54. Available at:
<https://doi.org/10.1136/bjism.2006.027599>.

Fain, J.N., Cheema, P., Tichansky, D.S. and Madan, A.K. (2008) “Stimulation of human omental adipose tissue lipolysis by growth hormone plus dexamethasone,” *Molecular and Cellular Endocrinology*, 295(1–2), pp. 101–105. Available at: <https://doi.org/10.1016/j.mce.2008.05.014>.

Feinberg, S.M., Dannenberg, T.B. and Malkiel, S. (1951) “Acth and cortisone in allergic manifestations,” *Journal of Allergy*, 22(3), pp. 195–210. Available at: [https://doi.org/10.1016/0021-8707\(51\)90015-9](https://doi.org/10.1016/0021-8707(51)90015-9).

- FLORINI, J.R. and BUYSKE, D.A. (1961) "Plasma protein binding of triamcinolone-H3 and hydrocortisone-4-C14.," *The Journal of biological chemistry*, 236, pp. 247–51.
- Frey, B.M. and Frey, F.J. (1990) "Clinical Pharmacokinetics of Prednisone and Prednisolone," *Clinical Pharmacokinetics*, 19(2), pp. 126–146. Available at: <https://doi.org/10.2165/00003088-199019020-00003>.
- Garg, D.C., Wagner, J.G., Sakmar, E., Weidler, D.J. and Albert, K.S. (1979) "Rectal and oral absorption of methylprednisolone acetate," *Clinical Pharmacology & Therapeutics*, 26(2), pp. 232–239. Available at: <https://doi.org/10.1002/cpt1979262232>.
- Goyal, N., Vohra, T. and Hurst, G.M. (2023) "The Jackson 5 System for Creating Rank Order Lists: Easy as A-B-C, 1-2-3," *Journal of Graduate Medical Education*, 15(3), pp. 394–395. Available at: <https://doi.org/10.4300/jgme-d-22-00776.1>.
- Greenbaum, D., McLachlan, A.J., Roubin, R.H., Moles, R. and Chaar, B. (2023) "Examining pharmacists' anti-doping knowledge and skills in assisting athletes to avoid unintentional use of prohibited substances," *International Journal of Pharmacy Practice*, 31(3), pp. 290–297. Available at: <https://doi.org/10.1093/ijpp/riad015>.
- Grzanka, A., Misiólek, M., Golusinski, W. and Jarzab, J. (2011) "Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis," *Eur Arch Otorhinolaryngol*, 268(2).
- Henry, H.L. and Norman, A.W. (2003) *Encyclopedia of hormones*. Academic Press.
- Hochhaus, G., Pörtner, M., Barth, J., Möllmann, H. and Rohdewald, P. (1990) "Oral Bioavailability of Triamcinolone Tablets and a Triamcinolone Diacetate Suspension," *Pharmaceutical Research*, 7(5), pp. 558–560. Available at: <https://doi.org/10.1023/A:1015889305157>.
- Holland, J.F., Frei, E., Kufe, D.W. and Society, A.C. (2003) *Cancer Medicine*. 6th ed. Bc Decker.
- Hostrup, M., Jessen, S., Onslev, J., Clausen, T. and Porsbjerg, C. (2017) "Two-week inhalation of budesonide increases muscle Na,K ATPase content but not endurance in response to terbutaline in men," *Scandinavian Journal of Medicine & Science in Sports*, 27(7), pp. 684–691. Available at: <https://doi.org/10.1111/sms.12677>.
- Hughes, D., Vlahovich, N., Welvaert, M., Tee, N., Harcourt, P., White, S., Vernec, A., Fitch, K. and Waddington, G. (2020) "Glucocorticoid prescribing habits of sports medicine physicians working in high-performance sport: a 30-nation survey," *British Journal of Sports Medicine*, 54(7), pp. 402–407. Available at: <https://doi.org/10.1136/bjsports-2019-101175>.

- Interpol (no date) *The use and trafficking of performance-enhancing drugs damages the integrity of sport.*, interpol.int.
- Ioannou, N. (2003) "Effects of dexamethasone on K(+)-evoked glutamate release from rat hippocampal slices," *Neurochemical Research*, 28(6), pp. 875–881. Available at: <https://doi.org/10.1023/a:1023271325728>.
- Jobe, A.H., Milad, M.A., Peppard, T. and Jusko, W.J. (2020) "Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India," *Clinical and Translational Science*, 13(2), pp. 391–399. Available at: <https://doi.org/10.1111/cts.12724>.
- Kim, J. and Jesus, O. de (2023) *Medication Routes of Administration*, StatPearls Publishing.
- Kim, J.K., Summer, S.N., Wood, W.M. and Schrier, R.W. (2001) "Role of Glucocorticoid Hormones in Arginine Vasopressin Gene Regulation," *Biochemical and Biophysical Research Communications*, 289(5), pp. 1252–1256. Available at: <https://doi.org/10.1006/bbrc.2001.6114>.
- Kovács, K., Földes, A. and Sawchenko, P.E. (2000) "Glucocorticoid Negative Feedback Selectively Targets Vasopressin Transcription in Parvocellular Neurosecretory Neurons," *The Journal of Neuroscience*, 20(10), pp. 3843–3852. Available at: <https://doi.org/10.1523/jneurosci.20-10-03843.2000>.
- Kozhuharov, V.R., Ivanov, K. and Ivanova, S. (2022) "Dietary Supplements as Source of Unintentional Doping," *BioMed Research International*, 2022(1), p. e8387271. Available at: <https://doi.org/10.1155/2022/8387271>.
- Kumala, A.P. and Widianingtyas (2018) "EVALUASI PENGGUNAAN OBAT KORTIKOSTEROID DI APOTEK HS 23 PERIODE FEBRUARI – APRIL 2018," *Jurnal Kefarmasian Akfarindo*, pp. 7–12. Available at: <https://doi.org/10.37089/jofar.v0i0.38>.
- Kuo, T., Harris, C.A. and Wang, J.-C. (2013) "Metabolic functions of glucocorticoid receptor in skeletal muscle," *Molecular and cellular endocrinology*, 380(1–2), pp. 79–88. Available at: <https://doi.org/10.1016/j.mce.2013.03.003>.
- Kusumah, I.P., Pribadi, F., Basudewo, D.P., Walukow, R.D., Atmadjaja, A., Iring, A.R., Maskim, D.N.F. and Nasyira, R. (2022) "PENGARUH PENGGUNAAN KORTIKOSTEROID PADA PASIEN GOUT: REVIEW LITERATUR," *Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal*, 12(4).
- Loew, D., Schuster, O. and Graul, E.H. (1986) "Dose-dependent pharmacokinetics of dexamethasone," *European Journal of Clinical Pharmacology*, 30(2), pp. 225–230. Available at: <https://doi.org/10.1007/BF00614309>.

- Maquirriain, J. (2010) "Epidemiological analysis of doping offences in the professional tennis circuit," *Journal of Occupational Medicine and Toxicology*, 5(1). Available at: <https://doi.org/10.1186/1745-6673-5-30>.
- Mareck, U., Fusshöller, G., Schertel, T., Petring, S., Huestis, M.A. and Thevis, M. (2022) "Risk of unintentional antidoping rule violations by consumption of hemp products," *Drug Testing and Analysis*, 15(1). Available at: <https://doi.org/10.1002/dta.3327>.
- Martínez-Sanz, J., Sospedra, I., Ortiz, C., Baladía, E., Gil-Izquierdo, A. and Ortiz-Moncada, R. (2017) "Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports," *Nutrients*, 9(10), p. 1093. Available at: <https://doi.org/10.3390/nu9101093>.
- Martiningsih, E.R. (2022) *Informasi Umum Tentang Penggunaan Obat Yang Aman*, keslan.kemkes.go.id.
- Oprea, A., Bonnet, N.C.G., Pollé, O. and Lysy, P.A. (2019) "Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency," *Therapeutic advances in endocrinology and metabolism*, 10.
- Papanek, P.E. and Raff, H. (1994) "Physiological increases in cortisol inhibit basal vasopressin release in conscious dogs," *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, 266(6), pp. R1744–R1751. Available at: <https://doi.org/10.1152/ajpregu.1994.266.6.r1744>.
- Peckett, A.J., Wright, D.C. and Riddell, M.C. (2011) "The effects of glucocorticoids on adipose tissue lipid metabolism," *Metabolism*, 60(11), pp. 1500–1510. Available at: <https://doi.org/10.1016/j.metabol.2011.06.012>.
- Pickup, M.E. (1979) "Clinical Pharmacokinetics of Prednisone and Prednisolone," *Clinical Pharmacokinetics*, 4(2), pp. 111–128. Available at: <https://doi.org/10.2165/00003088-197904020-00004>.
- Pokrywka, A., Berezovska, D., Lewandowska-Pachecka, S., Krzywański, J., Rynkowski, M., Wicka, M., Kwiatkowska, D. and Faiss, R. (2023) "Self-Declared and Measured Prevalence of Glucocorticoid Use in Polish Athletes," *Separations*, 10(3). Available at: <https://doi.org/10.3390/separations10030204>.
- Pope, C. and BPharm (2025) *Drug Half-life Explained*, *Drugs.com*.
- Riiser, A., Stensrud, T. and Andersen, L.B. (2023) "Glucocorticoids and physical performance: A systematic review with meta-analysis of randomized controlled trials," *Frontiers in sports and active living*, 5.
- Sapolsky, R.M., Romero, L.M. and Munck, A.U. (2000) "How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions," *Endocrine Reviews*, 21(1), pp. 55–89. Available at: <https://doi.org/10.1210/er.21.1.55>.

- Seckl, J.R. (2004) “11 β -hydroxysteroid dehydrogenases: changing glucocorticoid action,” *Current Opinion in Pharmacology*, 4(6), pp. 597–602. Available at: <https://doi.org/10.1016/j.coph.2004.09.001>.
- Simamora, S. and Lestari, Z. (2021) “PERESEPAN OBAT KORTIKOSTEROID PADA PASIEN RAWAT JALAN DI PUSKESMAS SIMPANG PERIUK KOTA LUBUK LINGGAU,” *JKPharm Jurnal Kesehatan Farmasi*, 3(1), pp. 17–24. Available at: <https://doi.org/10.36086/jpharm.v3i1.965>.
- Szeffler, S.J., Ebling, W.F., Georgitis, J.W. and Jusko, W.J. (1986) “Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults,” *European Journal of Clinical Pharmacology*, 30(3), pp. 323–329. Available at: <https://doi.org/10.1007/BF00541537>.
- Thomasson, R., Rieth, N., Jollin, L., Amiot, V., Lasne, F. and Collomp, K. (2011) “Short-term Glucocorticoid Intake and Metabolic Responses During Long-lasting Exercise,” *Hormone and Metabolic Research*, 43(03), pp. 216–222. Available at: <https://doi.org/10.1055/s-0030-1269919>.
- U.S. Food and Drug Administration (2011) *Fluticasone Furoate (Veramyst) Nasal Spray FDA Label*.
- U.S. Food and Drug Administration (2013) *FDA Approved Drug Products: Rayos Prednisone Delayed-Release Oral Tablets*.
- U.S. Food and Drug Administration (2018) *FDA Approved Drug Products: Pulmicort Budesonide Inhalation Powder*.
- U.S. Food and Drug Administration (2019) *FDA Approved Drug Products: Entocort Budesonide Oral Extended Release Capsules*.
- U.S. Food and Drug Administration (2019) *FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets*.
- U.S. Food and Drug Administration (2019) *Fluticasone Furoate (Arnuity Ellipta) FDA Label*.
- U.S. Food and Drug Administration (2019) *Fluticasone Propionate (Flonase) Nasal Spray FDA Label*.
- Ventura, R., Daley-Yates, P., Mazzoni, I., Collomp, K., Saugy, M., Buttgerit, F., Rabin, O. and Stuart, M. (2021) “A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes,” *British Journal of Sports Medicine*, 55(11), pp. 631–642. Available at: <https://doi.org/10.1136/bjsports-2020-103512>.
- Verneq, A., Healy, D., Banon, T. and Petroczi, A. (2024) “Prevalence of therapeutic use exemptions at the Olympic Games and Paralympic Games: an analysis of data from 2016 to 2022,” *British Journal of Sports Medicine*, 58(17), pp. 966–972. Available at: <https://doi.org/10.1136/bjsports-2024-108266>.

Vernece, A., Slack, A., Harcourt, P.R., Budgett, R., Duclos, M., Kinahan, A., Mjøsund, K. and Strasburger, C.J. (2020) “Glucocorticoids in elite sport: current status, controversies and innovative management strategies—a narrative review,” *British Journal of Sports Medicine*, 54(1), pp. 8–12. Available at: <https://doi.org/10.1136/bjsports-2018-100196>.

WADA The Prohibited List: 2018 (2018). WADA.

WADA World Anti-Doping Code: 2018 (2018). WADA.

World Anti-Doping Code International Standard Prohibited List 2024 (2024). WADA.

Werumeus Buning, J., Touw, D.J., Brummelman, P., Dullaart, R.P.F., van den Berg, G., van der Klauw, M.M., Kamp, J., Wolffenbuttel, B.H.R. and van Beek, A.P. (2017) “Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial,” *Metabolism*, 71, pp. 7–16. Available at: <https://doi.org/10.1016/j.metabol.2017.02.005>.

Wolkowitz, O.M. (1990) “Prednisone Effects on Neurochemistry and Behavior,” *Archives of General Psychiatry*, 47(10), p. 963. Available at: <https://doi.org/10.1001/archpsyc.1990.01810220079010>.

World Anti-Doping Agency (WADA) (2025) *Glucocorticoids and Therapeutic Use Exemptions*.

World Anti-Doping Code : 2021 (2021). WADA.

WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST 2024 (2024). WADA.

Xu, J., Winkler, J., Sabarinath, S.N. and Derendorf, H. (2008) “Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone,” *AAPS J*, 10(2).

Yasir, M., Goyal, A. and Sonthalia, S. (2023) *Corticosteroid Adverse Effects, StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing*.

Zorgati, H., Prieur, F., Vergniaud, T., Cottin, F., Do, M.-C., Labsy, Z., Amarantini, D., Gagey, O., Lasne, F. and Collomp, K. (2014) “Ergogenic and metabolic effects of oral glucocorticoid intake during repeated bouts of high-intensity exercise,” *Steroids*, 86, pp. 10–15. Available at: <https://doi.org/10.1016/j.steroids.2014.04.008>.